Biallelic Variants of MRPS36 Cause a New Form of Leigh Syndrome
Serena Galosi, Cecilia Mancini, Anna Commone, Paolo Calligari, Viviana Caputo, Francesca Nardecchia, Claudia Carducci, Lambertus P. van den Heuvel, Simone Pizzi, Alessandro Bruselles, Marcello Niceta, Simone Martinelli, Richard J. Rodenburg, Marco Tartaglia, Vincenzo Leuzzi Abstract
Background
The MRPS36 gene encodes a recently identified component of the 2‐oxoglutarate dehydrogenase complex (OGDHC), a key enzyme of the Krebs cycle catalyzing the oxidative decarboxylation of 2‐oxoglutarate to succinyl‐CoA. Defective OGDHC activity causes a clinically variable metabolic disorder characterized by global developmental delay, severe neurological impairment, liver failure, and early‐onset lactic acidosis.
Methods
We investigated the molecular cause underlying Leigh syndrome with bilateral striatal necrosis in two siblings through exome sequencing. Functional studies included measurement of the OGDHC enzymatic activity and MRPS36 mRNA levels in fibroblasts, assessment of protein stability in transfected cells, and structural analysis. A literature review was performed to define the etiological and phenotypic spectrum of OGDHC deficiency.
Results
In the two affected brothers, exome sequencing identified a homozygous nonsense variant (c.283G>T, p.Glu95*) of MRPS36. The variant did not affect transcript processing and stability, nor protein levels, but resulted in a shorter protein lacking nine residues that contribute to the structural and functional organization of the OGDHC complex. OGDHC enzymatic activity was significantly reduced.
The review of previously reported cases of OGDHC deficiency supports the association of this enzymatic defect with Leigh phenotypic spectrum and early‐onset movement disorder. Slightly elevated plasma levels of glutamate and glutamine were observed in our and literature patients with OGDHC defect.
Conclusions
Our findings point to MRPS36 as a new disease gene implicated in Leigh syndrome. The slight elevation of plasma levels of glutamate and glutamine observed in patients with OGDHC deficiency represents a candidate metabolic signature of this neurometabolic disorder. © 2024 International Parkinson and Movement Disorder Society.